From the Divisions of ∗Radiology

†Medical Image Computing, German Cancer Research Center (DKFZ)

‡Medical Faculty, University of Heidelberg

§Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany

∥Department of Biomedical Engineering, Faculty of Electrical Engineering and Communication, Brno University of Technology, Brno, Czech Republic

¶Diagnostic and Interventional Radiology

#Department of Internal Medicine V, Section Multiple Myeloma

∗∗Institute of Human Genetics

††Department of Diagnostic and Interventional Radiology With Nuclear Medicine, Thorax Clinic at Heidelberg University Hospital, Heidelberg

‡‡Department of Diagnostic and Interventional Radiology, Eberhard Karls University, Tuebingen University Hospital, Tuebingen

§§National Center for Tumor Diseases (NCT)

∥∥Pattern Analysis and Learning Group, Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.

Received for publication July 27, 2022; and accepted for publication, after revision, August 28, 2022.

F.T.K. and K.M.-H. contributed equally.

Conflicts of interest and sources of funding: This study did not receive specific funding. The following relationships are disclosed: M.W., P.N., N.S., K.-C. K., J.K., V.W., T.H., M.G., J.C., K.S.Z., F.B., T.N., M.D., L.T.R., A.J., K.S., E.K.M., N.W., S.A., M.H., T.F.W., S.D., F.T.K., and K.M.-H. have nothing to declare. S.S. reported receiving travel grants or honoraria for presentations from Celgene, BMS, Janssen, Takeda, and Amgen. H.G. reported receiving grants and/or provision of investigational medicinal product from Amgen, Array Biopharma/Pfizer, BMS, Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, and Sanofi; receiving research support from Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme, MorphoSys AG, Pfizer, Sanofi, Takeda, and Novartis; being on the advisory boards of Adaptive Biotechnology, Amgen, BMS, Janssen, Sanofi, and receiving honoraria from Amgen, BMS, Chugai, GlaxoSmithKline, Janssen, Novartis, Sanofi and Pfizer. H.-P.S. declares receiving consulting fee or honorarium from Siemens, Curagita, Profound, and Bayer; declares receiving travel support from Siemens, Curagita, Profound, and Bayer; is a board member of Curagita; provides consultancy for Curagita and Bayer; declares receiving grants/grants pending from BMBF, Deutsche Krebshilfe, Dietmar-Hopp-Stiftung, and Roland-Ernst-Stiftung; and declares receiving payment for lectures from Siemens, Curagita, Profound, and Bayer.

Correspondence to: Markus Wennmann, MD, Division of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. E-mail: [email protected].

Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.investigativeradiology.com).